➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
McKinsey
McKesson
Moodys
Medtronic
Dow

Last Updated: June 16, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Beloranib


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug Beloranib?

Beloranib is an investigational drug.

There have been 8 clinical trials for Beloranib. The most recent clinical trial was a Phase 2 trial, which was initiated on September 1st 2014.

The most common disease conditions in clinical trials are Prader-Willi Syndrome, Overweight, and Obesity. The leading clinical trial sponsors are Zafgen, Inc. and [disabled in preview].

There are seventy-four US patents protecting this investigational drug and eight hundred and sixteen international patents.

Recent Clinical Trials for Beloranib
TitleSponsorPhase
An Efficacy and Safety Study of Beloranib in Obese Subjects With Type 2 Diabetes MellitusZafgen, Inc.Phase 2
Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi SyndromeZafgen, Inc.Phase 3
An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Hypothalamic InjuryZafgen, Inc.Phase 2

See all Beloranib clinical trials

Clinical Trial Summary for Beloranib

Top disease conditions for Beloranib
Top clinical trial sponsors for Beloranib

See all Beloranib clinical trials

US Patents for Beloranib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Beloranib   Get Started Free METAP2 inhibitors and methods of treating obesity SynDevRx, Inc. (Cambridge, MA)   Get Started Free
Beloranib   Get Started Free Glial cell line derived neurotrophic factor, obesity, and obesity-related diseases and conditions Emory University (Atlanta, GA) The United States Geovernment represented by the United States Department of Veterans Affairs (Washington, DC)   Get Started Free
Beloranib   Get Started Free Methods for treating subjects with prader-willi syndrome or smith-magenis syndrome Essentialis, Inc. (Redwood City, CA)   Get Started Free
Beloranib   Get Started Free Anti-Laminin4 antibodies specific for LG4-5 PROTHENA BIOSCIENCES LIMITED (Dublin, IE)   Get Started Free
Beloranib   Get Started Free Controlled release dosage form TRIASTEK, INC. (Nanjing, CN)   Get Started Free
Beloranib   Get Started Free Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk ELCELYX THERAPEUTICS, INC. (San Diego, CA)   Get Started Free
Beloranib   Get Started Free ACC inhibitors and uses thereof Gilead Apollo, LLC (Foster City, CA)   Get Started Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Beloranib

Drugname Country Document Number Estimated Expiration Related US Patent
Beloranib Argentina AR095828 2033-04-10   Get Started Free
Beloranib Australia AU2014250983 2033-04-10   Get Started Free
Beloranib Brazil BR112015025892 2033-04-10   Get Started Free
Beloranib Canada CA2908993 2033-04-10   Get Started Free
Beloranib China CN105431426 2033-04-10   Get Started Free
Beloranib Denmark DK2984085 2033-04-10   Get Started Free
Beloranib Eurasian Patent Organization EA033912 2033-04-10   Get Started Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Moodys
Medtronic
AstraZeneca
Johnson and Johnson
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.